Oruka Therapeutics, Inc. (ORKA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $61.00K; Additional Paid in CapitalUSD $1.38B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.70M; Retained Earnings (Accumulated Deficit)USD $-262.18M.
- 2026-03-31: Common Stock, Value, IssuedUSD $50.00K; Additional Paid in CapitalUSD $705.20M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-480.00K; Retained Earnings (Accumulated Deficit)USD $-220.98M.
- 2025-12-31: Common Stock, Value, IssuedUSD $49.00K; Additional Paid in CapitalUSD $657.56M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $546.00K; Retained Earnings (Accumulated Deficit)USD $-189.16M.
- 2025-09-30: Common Stock, Value, IssuedUSD $48.00K; Additional Paid in CapitalUSD $643.20M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $185.00K; Retained Earnings (Accumulated Deficit)USD $-159.57M.
Oruka Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Additional Paid in Capital, Common Stock USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $61.00K | $1.38B | $-1.70M | $-262.18M | $1.11B | (m) | 3 month · $7.28M | (m) | (m) | (m) |
| 2026-03-31 | $50.00K | $705.20M | $-480.00K | $-220.98M | $486.72M | (m) | 3 month · $6.97M | (m) | (m) | (m) |
| 2025-12-31 | $49.00K | $657.56M | $546.00K | $-189.16M | $471.93M | (m) | 12 month · $14.18M | 12 month · $10.06M | (m) | (m) |
| 2025-09-30 | $48.00K | $643.20M | $185.00K | $-159.57M | $486.79M | (m) | 3 month · $3.57M | (m) | (m) | (m) |
| 2025-06-30 | $37.00K | $470.00M | $-27.00K | $-129.30M | $343.64M | (m) | 3 month · $3.40M | (m) | (m) | (m) |
| 2025-03-31 | $37.00K | $466.49M | $-6.00K | $-104.72M | $364.73M | (m) | 3 month · $3.47M | (m) | (m) | (m) |
| 2024-12-31 | $37.00K | $463.02M | $-41.00K | $-83.72M | $382.22M | 11 month · $20.50M 11 month · $20.50M | 11 month · $4.56M 11 month · $4.56M | 11 month · $10.36M 11 month · $10.36M | (m) | (m) |
| 2024-09-30 | $35.00K | $397.35M | (m) | $-57.94M | $342.37M | 3 month · $20.48M | 3 month · $1.75M | (m) | (m) | (m) |
| 2024-06-30 | $14.00K | (m) | (m) | $-193.43M | $-28.98M | (m) | 3 month · $321.00K | (m) | $225.99M | (m) |
| 2024-03-31 | $14.00K | (m) | (m) | $-190.75M | $-7.06M | (m) | 2 month · $17.00K 2 month · $17.00K 3 month · $114.00K | (m) | $225.86M | (m) |
| 2024-02-06 | (m) | $1.00K | (m) | (m) | $1.00K | (m) | (m) | (m) | (m) | (m) |
| 2024-02-05 | (m) | (m) | (m) | (m) | $1.00K | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $14.00K | (m) | (m) | $-188.74M | $37.02M | (m) | 3 month · $141.00K 12 month · $686.00K | (m) | $225.75M | (m) |
| 2023-09-30 | $14.00K | (m) | (m) | $-187.65M | $37.97M | (m) | 3 month · $154.00K | (m) | $225.61M | (m) |
| 2023-06-30 | $14.00K | (m) | (m) | $-186.23M | $39.24M | (m) | 3 month · $187.00K | (m) | $225.45M | (m) |
| 2023-03-31 | $14.00K | (m) | (m) | $-184.75M | $40.53M | (m) | 3 month · $204.00K | (m) | $225.26M | (m) |
| 2022-12-31 | $14.00K | (m) | (m) | $-183.40M | $41.67M | (m) | 3 month · $120.00K 12 month · $556.00K | (m) | $225.06M | (m) |
| 2022-09-30 | $14.00K | (m) | (m) | $-182.23M | $42.73M | (m) | 3 month · $97.00K | (m) | $224.94M | (m) |
| 2022-06-30 | $14.00K | (m) | (m) | $-179.90M | $44.96M | (m) | 3 month · $172.00K | (m) | $224.84M | (m) |
| 2022-03-31 | $14.00K | (m) | (m) | $-176.75M | $47.94M | (m) | 3 month · $167.00K | (m) | $224.67M | (m) |
| 2021-12-31 | $14.00K | (m) | (m) | $-173.48M | $51.04M | (m) | 3 month · $119.00K 12 month · $497.00K | (m) | $224.50M | (m) |
| 2021-09-30 | $14.00K | (m) | (m) | $-167.80M | $56.60M | (m) | 3 month · $104.00K | (m) | $224.39M | (m) |
| 2021-06-30 | $14.00K | (m) | (m) | $-163.09M | $61.21M | (m) | 3 month · $133.00K | (m) | $224.28M | (m) |
| 2021-03-31 | $14.00K | (m) | (m) | $-158.25M | $65.91M | (m) | 3 month · $141.00K | (m) | $224.15M | (m) |
| 2020-12-31 | $10.00K | (m) | (m) | $-154.15M | $46.52M | (m) | 3 month · $18.00K 12 month · $43.00K | (m) | $200.66M | (m) |
| 2020-09-30 | $9.00K | (m) | (m) | $-149.03M | $50.45M | (m) | 3 month · $5.00K | (m) | $199.47M | (m) |
| 2020-06-30 | $2.00K | (m) | (m) | $-147.04M | $10.30M | (m) | 3 month · $4.00K | (m) | $157.34M | (m) |
| 2020-03-31 | $2.00K | (m) | (m) | $-145.74M | $6.31M | (m) | 3 month · $16.00K | (m) | $152.04M | (m) |
| 2019-12-31 | $2.00K | (m) | (m) | $-144.42M | $7.61M | (m) | 3 month · $27.00K 12 month · $151.00K | (m) | $152.02M | (m) |
| 2019-09-30 | $2.00K | (m) | (m) | $-143.19M | $8.80M | (m) | 3 month · $29.00K | (m) | $151.99M | (m) |
| 2019-06-30 | $1.00K | (m) | (m) | $-142.03M | $9.19M | (m) | 3 month · $45.00K | (m) | $151.22M | (m) |
| 2019-03-31 | $1.00K | (m) | (m) | $-140.60M | $7.32M | (m) | 3 month · $50.00K | (m) | $147.91M | (m) |
| 2018-12-31 | $1.00K | (m) | (m) | $-138.93M | $6.03M | (m) | 3 month · $58.00K 12 month · $273.00K | (m) | $144.97M | (m) |
| 2018-09-30 | $14.00K | (m) | (m) | $-137.44M | $7.46M | (m) | 3 month · $58.00K | (m) | $144.89M | (m) |
| 2018-06-30 | $14.00K | (m) | (m) | $-135.85M | $9.00M | (m) | 3 month · $60.00K 6 month · $157.00K | (m) | $144.84M | (m) |
| 2018-03-31 | $14.00K | (m) | (m) | $-133.74M | $11.05M | (m) | 3 month · $97.00K | (m) | $144.78M | (m) |
| 2017-12-31 | $12.00K | (m) | $-2.00K | $-131.00M | $10.28M | (m) | 3 month · $119.00K 12 month · $458.00K | (m) | $141.27M | (m) |
| 2017-09-30 | $12.00K | (m) | $-3.00K | $-126.80M | $14.35M | (m) | 3 month · $119.00K 9 month · $339.00K | (m) | $141.15M | (m) |
| 2017-06-30 | $10.00K | (m) | $-5.00K | $-122.37M | $14.75M | (m) | 3 month · $119.00K 6 month · $220.00K | (m) | $137.11M | (m) |
| 2017-03-31 | $9.00K | (m) | $-9.00K | $-116.85M | $18.04M | (m) | 3 month · $101.00K | (m) | $134.88M | (m) |
| 2016-12-31 | $9.00K | (m) | $-19.00K | $-112.51M | $22.19M | (m) | 12 month · $576.00K | (m) | $134.72M | 12 month · $11.00K |
| 2016-09-30 | $9.00K | (m) | $-6.00K | $-108.27M | $26.48M | (m) | 9 month · $605.00K | (m) | $134.74M | 9 month · $11.00K |
| 2016-06-30 | $9.00K | (m) | $13.00K | $-103.61M | $30.89M | (m) | 6 month · $338.00K | (m) | $134.48M | 6 month · $11.00K |
| 2016-03-31 | $9.00K | (m) | $6.00K | $-99.71M | $34.58M | (m) | 3 month · $155.00K | (m) | $134.28M | (m) |
| 2015-12-31 | $9.00K | (m) | (m) | $-96.07M | $38.07M | (m) | 12 month · $599.00K | (m) | $134.13M | (m) |
| 2015-09-30 | $9.00K | (m) | (m) | $-92.90M | $41.09M | (m) | 9 month · $454.00K | (m) | $133.98M | (m) |
| 2015-06-30 | $63.00K | (m) | (m) | $-90.08M | $43.76M | (m) | 6 month · $305.00K | (m) | $133.78M | (m) |
| 2015-03-31 | $21.00K | (m) | (m) | $-87.37M | $12.13M | (m) | 3 month · $130.00K | (m) | $99.47M | (m) |
| 2014-12-31 | $3.00K | (m) | (m) | $-84.62M | $14.74M | (m) | 12 month · $647.00K | (m) | $99.36M | (m) |
| 2014-09-30 | $21.00K | $99.19M | (m) | $-82.01M | $17.20M | (m) | 9 month · $491.00K | (m) | (m) | (m) |
| 2014-06-30 | $21.00K | $99.03M | (m) | $-79.73M | $19.32M | (m) | 6 month · $330.00K | (m) | (m) | (m) |
| 2014-03-31 | $21.00K | $98.83M | (m) | $-77.32M | $21.53M | (m) | 3 month · $158.00K | (m) | (m) | (m) |
| 2013-12-31 | $16.00K | $90.50M | (m) | $-74.93M | $15.58M | (m) | 12 month · $283.00K | (m) | $90.50M | (m) |
| 2013-09-30 | $13.00K | $90.34M | (m) | $-71.99M | $18.37M | (m) | 9 month · $125.00K | (m) | (m) | (m) |
| 2013-06-30 | $10.00K | $90.29M | (m) | $-70.26M | $20.03M | (m) | 6 month · $76.00K | (m) | (m) | (m) |
| 2013-03-31 | $3.00K | $72.37M | (m) | $-69.06M | $3.31M | (m) | 3 month · $42.00K | (m) | (m) | (m) |
| 2012-12-31 | $3.00K | $70.90M | (m) | $-67.99M | $2.91M | (m) | 12 month · $306.00K | (m) | (m) | (m) |
| 2012-09-30 | $15.00K | $70.31M | (m) | $-67.15M | $3.18M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $12.00K | $69.50M | (m) | $-66.23M | $3.29M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $12.00K | $69.42M | (m) | $-65.08M | $4.36M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $2.00K | $69.40M | (m) | $-63.67M | $5.73M | (m) | 12 month · $308.00K | (m) | (m) | (m) |
| 2011-09-30 | $11.00K | $67.84M | (m) | $-62.04M | $5.73M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $11.00K | $67.76M | (m) | $-60.22M | $7.54M | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $9.00K | $65.07M | (m) | $-58.31M | $6.77M | (m) | 12 month · $458.00K | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | $7.41M | (m) | 12 month · $845.00K | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | $-38.18M | (m) | 12 month · $545.00K | 12 month · $399.00K | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | $-19.69M | (m) | 12 month · $50.00K | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | (m) | (m) | $-5.74M | 12 month · $-17.00K | 12 month · $39.00K | (m) | (m) | (m) |
| 2005-12-31 | (m) | (m) | (m) | (m) | $-678.00K | (m) | (m) | (m) | (m) | (m) |
| 2004-12-31 | (m) | (m) | (m) | (m) | $-619.00K | (m) | (m) | (m) | (m) | (m) |
| 2003-12-31 | (m) | (m) | (m) | (m) | $-115.00K | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |